ENDOLOGIX INC /DE/

Form 4 July 29, 2009

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer

subject to Section 16. Form 4 or Form 5

obligations See Instruction

may continue.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * ELLIOTT ASSOCIATES, L.P.

> (First) (Middle)

712 FIFTH AVE

(Last)

(Street)

2. Issuer Name and Ticker or Trading Symbol

ENDOLOGIX INC /DE/ [ELGX]

3. Date of Earliest Transaction (Month/Day/Year) 07/27/2009

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to

Issuer

(Check all applicable)

OMB APPROVAL

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

_X__ 10% Owner Director Other (specify Officer (give title below)

6. Individual or Joint/Group Filing(Check Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

NEW YORK, NY 10019

(City)	(State)	(Zip) Tabl	e I - Non-D	erivative (Securi	ties Acqu	ired, Disposed of	, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/27/2009		Code V S	Amount 11,295	(D)	Price \$ 4.95	2,521,769	I	See (1)
Common Stock	07/27/2009		S	2,200	D	\$ 4.955	2,519,569	I	See (1)
Common Stock	07/27/2009		S	11,360	D	\$ 4.96	2,508,209	I	See (1)
Common Stock	07/27/2009		S	2,280	D	\$ 4.965	2,505,929	I	See (1)
Common Stock	07/27/2009		S	1,360	D	\$ 4.97	2,504,569	I	See (1)
	07/27/2009		S	2,360	D	\$ 4.98	2,502,209	I	See (1)

Common Stock								
Common Stock	07/27/2009	S	1,040	D	\$ 4.99	2,501,169	I	See (1)
Common Stock	07/27/2009	S	5,160	D	\$ 4.995	2,496,009	I	See (1)
Common Stock	07/27/2009	S	920	D	\$ 5	2,495,089	I	See (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (Instr.	8)	5. nNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Tit Amou Under Secur (Instr	int of rlying	8. Price of Derivative Security (Instr. 5)
				Code	V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

Reporting Owners

Reporting Owner Name / Address	Relationships							
FB	Director	10% Owner	Officer	Other				
ELLIOTT ASSOCIATES, L.P.								
712 FIFTH AVE		X						
NEW YORK NY 10019								

Signatures

Elliot Greenberg, VP of Braxton Associates, Inc., as GP of Elliott Capital Advisors, L.P., as GP of Elliott Associates, L.P.

07/29/2009

9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

**Signature of Reporting Person Date

Reporting Owners 2

Edgar Filing: ENDOLOGIX INC /DE/ - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Elliott Associates, L.P ("Elliott"). indirectly owns the 2,495,089 shares of Common Stock of Endologix, Inc. (the "Company") reported on this Form 4 through its subsidiary, The Liverpool Limited Partnership, a Bermuda limited partnership.

Remarks:

On July 27, 2009, Elliott sold an aggregate of 37,975 shares of Common Stock of Endologix, Inc. (the "Company") as reported on this Form 4. Elliott does not currently have any plans to sell any additional shares of Common Stock of the Company, but reserves the right to do so as market conditions or other circumstances change.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.